Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?
Gene and cell therapy products approved over the past decade in Europe and North America have provided new therapeutic options for single gene disorders and for hematologic malignancies. Lessons learned, and limitations identified, are reviewed.
Guardado en:
Autor principal: | Katherine A. High |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f171a9d52474522a7b4c78c99203c64 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Two decades with omalizumab: what we still have to learn
por: Incorvaia C, et al.
Publicado: (2018) -
COVID-19 pandemic. What have we learned?
por: Cristina Calvo, et al.
Publicado: (2021) -
What we have learned and what the future holds: Perspectives on the COVID-19
por: Adrián Camacho-Ortiz
Publicado: (2021) -
What Have We Learned about the Microbiomes of Indoor Environments?
por: Brent Stephens
Publicado: (2016) -
Fifteen years of new growth economics: what have we learned?
por: Sala-I-Martin, Xavier
Publicado: (2019)